Clinical Trial Update: Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a three-drug combination of levocetirizine, capecitabine, and bevacizumab in refractory colorectal cancer has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• Levocetirizine (Levocetirizine)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Colorectal Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2017-02-13